Association of exosomal miR17-92a cluster and target genes with breast cancer risk.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI:10.1080/14796694.2025.2539627

Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen

{"title":"Association of exosomal miR17-92a cluster and target genes with breast cancer risk.","authors":"Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen","doi":"10.1080/14796694.2025.2539627","DOIUrl":null,"url":null,"abstract":"Background: The present study aimed to explore the roles of exosomal microRNAs (miR-17, miR-19b, and miR-92a) and two target genes (PTEN and TGFβR2) in breast cancer risk.Methods: Expression analysis was performed using real-time PCR in a study cohort of 500 patients and 500 age- and sex-matched healthy controls.Results: The selected miRNAs (miR-17, p < 0.01; miR-19b, p < 0.01; miR-92a, p < 0.01) and TGFβR2 (p < 0.01) revealed an upregulated expression pattern, whereas downregulation of PTEN (p < 0.05) was observed in cancer patients compared to controls. A significant upregulated expression of miR-17, miR-92a, and TGFβR2 was observed in advanced clinical stages, advanced T-stage, advanced N-stage, and advanced M-stage in breast cancer patients.Conclusions: These findings demonstrate the oncogenic potential of the selected miRNAs, contributing to breast carcinogenesis. Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2731-2746"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2539627","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The present study aimed to explore the roles of exosomal microRNAs (miR-17, miR-19b, and miR-92a) and two target genes (PTEN and TGFβR2) in breast cancer risk.

Methods: Expression analysis was performed using real-time PCR in a study cohort of 500 patients and 500 age- and sex-matched healthy controls.

Results: The selected miRNAs (miR-17, p < 0.01; miR-19b, p < 0.01; miR-92a, p < 0.01) and TGFβR2 (p < 0.01) revealed an upregulated expression pattern, whereas downregulation of PTEN (p < 0.05) was observed in cancer patients compared to controls. A significant upregulated expression of miR-17, miR-92a, and TGFβR2 was observed in advanced clinical stages, advanced T-stage, advanced N-stage, and advanced M-stage in breast cancer patients.

Conclusions: These findings demonstrate the oncogenic potential of the selected miRNAs, contributing to breast carcinogenesis. Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.

查看原文本刊更多论文

外泌体miR17-92a簇和靶基因与乳腺癌风险的关系

背景：本研究旨在探讨外泌体microRNAs （miR-17、miR-19b和miR-92a）和两个靶基因（PTEN和TGFβR2）在乳腺癌风险中的作用。方法：对500名患者和500名年龄和性别匹配的健康对照进行实时PCR表达分析。结果：选定的miRNAs (miR-17, p)，这些发现证明了选定的miRNAs的致癌潜力，有助于乳腺癌的发生。进一步分析表明，在所选分子的表达失调与细胞增殖和转移增加之间存在关联。miR-17和TGFβR2具有良好的诊断潜力，auc分别为0.708和0.909。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.